AVITA’s RECELL® System trial on DFU patients yields favorable results
Category: #health  By Mateen Dalal  Date: 2019-07-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

AVITA’s RECELL® System trial on DFU patients yields favorable results

The 26-week observational study included 16 subjects at three different hospitals in the UK

Global regenerative medicine company AVITA Medical has recently announced that their open-label study of the latest RECELL® System, conducted on 16 subjects with diabetic foot ulcers (DFUs) who had been unresponsive to standard care treatments, yielded promising results.

Apparently, the RECELL® Autologous Cell Harvesting Device uses a small portion of a patient’s own skin to formulate Spray-On Skin™ Cells at the point-of-care.

Mr. Tawqeer Rashid, Consultant Vascular and Endovascular Surgeon at the Manchester Royal Infirmary, was quoted saying that there was a definite need to find new cures for chronic conditions like DFUs, since they deeply impact the patients’ lives.

Reportedly, Rashid made the announcement at the 11th annual Japanese Society of Limb Salvage & Podiatric Medicine conference held in Japan on June 28 & 29, 2019. He also added that the RECELL® System showed favorable potential in speeding up the healing of DFUs.

Citing reliable sources, the 26-week observational study included 16 subjects at three different hospitals in the UK, including Manchester Royal Infirmary, Northwick Park Hospital and Kings College Hospital. Subjects under observation suffered from chronic DFUs ranging from 5 to 33 sq.cm, with variable depths, with and without infection, inclusive of tendon and bone exposure, that had not been responsive to various standard treatments.

The patients were then treated with the RECELL® System which was applied over the affected area.

Evidently, the study generated encouraging results, including an 83% average wound size reduction in all the patients at the end of the 26th week and 100% recovery in half of the patients with an average period of 14 weeks. The treatment seems to have provided a satisfactory safety profile and excellent patient and physician scores were reported following the study. 

AVITA Medical CEO Michael Perry stated that successful conclusions from the study demonstrate RECELL® System’s versatility and the company is committed towards exploring how their new regenerative technology can be further developed for advance patient care. 

Source credit: https://www.avitamedical.com/uploads/pdf/PR-20190701.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...

Motorola Solutions buys WatchGuard to expand video security portfolio
Motorola Solutions buys WatchGuard to expand video security portfolio
By Mateen Dalal

WatchGuard’s solutions allow law enforcement users to manage high-quality video evidence Motorola Solutions, Inc., the US based data communications and telecommunications equipment provider, has recently announced the acquisition of WatchGuard...

Cara begins Phase 2 trial of pruritus treatment in dermatitis patients
Cara begins Phase 2 trial of pruritus treatment in dermatitis patients
By Mateen Dalal

The study is formulated to evaluate the safety and efficacy of Oral KORSUVA for moderate to severe pruritus Biopharmaceutical firm Cara Therapeutics Inc. has reportedly announced the initiation of their Phase 2 trial of Oral KORSUVATM for pruritus t...